A previous study by Ek et al. which used VCR/methylprednisolone/ASP in combination to assess the efficacy of the anti-CD19 immunotoxin B43-PAP in a preclinical model of ALL demonstrated the usefulness of testing new agents in combination with established drugs. Here, CD19 is linked to acute lymphoblastic leukemia.